Should You Buy Guardant Health Before Feb. 19?

Core Insights - Guardant Health is experiencing significant growth, with shares rising substantially over the past six months and recent key collaborations enhancing its market position [1][2] - The company is at an inflection point, making it an attractive investment opportunity for growth investors [2][3] Financial Performance - In Q3 2025, Guardant Health's core oncology business achieved positive free cash flow, one quarter ahead of its target, and management anticipates maintaining this positive cash flow into Q4 and throughout 2026 [3] - The current market capitalization of Guardant Health is $14 billion, with a gross margin of 63.76% [2] Partnerships and Collaborations - Guardant Health is collaborating with Path Group to market the Shield blood test for colorectal cancer screening across more than 250 health systems [4] - The partnership with Quest Diagnostics is set to expand in Q1 2026, aiming to make the Shield test available to U.S. physicians and patients [4] Regulatory Approvals - The company received FDA approval for Guardant360 CDx as a companion diagnostic for Pfizer's Braftovi in combination with Eli Lilly's Erbitux, marking a significant milestone in colorectal cancer treatment [5] Market Outlook - Although the recent partnerships and FDA approval will not impact Q4 results, they are expected to create positive momentum for the stock in the long term [6] - Investors are advised to consider the long-term investment thesis for Guardant Health, as immediate results may not reflect the company's future potential [7]